<?xml version="1.0" encoding="UTF-8"?>
<p>Dengue virus (DENV) causes a considerable burden to public health worldwide, consisting of 60 to 100 million symptomatic infections, 14,000 to 20,000 deaths per year, and of a global annual cost of about 9 billion dollars [
 <xref rid="pcbi.1006831.ref001" ref-type="bibr">1</xref>, 
 <xref rid="pcbi.1006831.ref002" ref-type="bibr">2</xref>]. Four distinct DENV serotypes exist; infection by one of them confers life-long immunity to that serotype and temporary cross-immunity to others. However, secondary dengue infections with different serotypes are more likely to cause severe illness because of an immune process known as antibody-dependent enhancement (ADE), where pre-existing cross-reacting antibodies do not neutralize but rather enhance viral replication [
 <xref rid="pcbi.1006831.ref003" ref-type="bibr">3</xref>].
</p>
